Seroprevalence was highest in studies conducted in Central Africa compared to Southern Africa, West Africa, North Africa and East Africa respectively. This systematic review and meta-analysis therefore sought to estimate the current anti-SARS-CoV-2 antibody seroprevalence in Africa. The highest anti-SARS-CoV-2 antibody seroprevalence was 63%20 in the Republic of South Africa (RSA), while the lowest anti-SARS-CoV-2 seroprevalence recorded was 0%24 in Libya (Figure 2). Based on African region subgroup analysis, seroprevalence of anti-SARS-CoV-2 antibodies was higher in studies conducted in Central Africa (41%) compared to Southern Africa (34%), West Africa (25%), North Africa (13%) and East Africa (12%). More rigorously executed anti-SARS-CoV-2 seroprevalence studies in Africa are needed to monitor progressive changes in respective countries.

Source: The North Africa Journal July 07, 2021 03:11 UTC